In the Original Investigation by Graham et al titled “Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation,” published online October 3, 2016, in JAMA Internal Medicine,1 the graph lines in Figure 1, panels B, C, and D, were mislabeled. In all graphs, the blue lines correctly indicate rivaroxaban, and the black lines correctly indicate dabigatran. This article was corrected online.
Error in Graph Line Labels. JAMA Intern Med. 2016;176(11):1729. doi:10.1001/jamainternmed.2016.7319